Velpatasvir (velpatasvir) is a new drug developed by Gilead Inc. It is used in the treatment of hepatitis C. This remedy is especially effective for genotypes 2 and 3 of hepatitis. And while in medicine he has no equal in strength.

The combination of sofosbuvir (400 mg) with velpatasvir (100 mg) is designed to combat any genotype of the hepatitis C virus and gives a 100% result, even if the previous treatment did not bring success. It was developed in the United States by the pharmaceutical giant Gilead Inc. and is available in the form of tablets called the Epclusa.

Sofosbuvir in this preparation inhibits RNA polymerases, with which the virus copies its RNA, and Velpatasvir acts on the NS5B polymerase, thereby interrupting the introduction of the viral genome into healthy cells.
Where to buy velpatasvir and sofosbuvir in the combined preparation?

It is quite difficult to buy Epclusa pills since they cost more than 60,000 euros for a three-month course of treatment, which, as you understand, is simply not affordable for the vast majority of patients. Fortunately, in 2017, Gilead provided Indian companies NATCO PHARMA and HETERO with a non-exclusive license to reproduce licensed generics: Velpanat (NATCO) and VELASOF (HETERO). Buy velpatasvir + sofosbuvir is now possible in India at the most appropriate price. The combination, saving for many patients - sofosbuvir + velpatasvir - can be bought on the website of a large Indian distributor network WWW.MEDIXOCENTRE.COM.
To order the generic Epclusa on the website of an Indian company, you need to have documents confirming that you really need treatment for hepatitis C.

Contraindications

As you can see, the described remedy is indispensable in the fight against a serious illness. But before you buy "Velpatasvir" or its combination with sofosbuvir, you should know that experts do not recommend using the drug for women during pregnancy and lactation, as well as for men, in the case of pregnancy partner. Do not prescribe this tool and patients under the age of 18 years, as well as having individual intolerance to the active components of the drug.